Cancer News and Research

Latest Cancer News and Research

Black people more likely to exhaust financial resources for cancer therapy than whites: Study

In a new study published online in the journal Cancer, it was said that when faced with life-threatening cancer, minority patients like blacks may be more likely to drain their bank accounts to extend life than whites.

26 Apr 2011

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Vertex pharmaceuticals jumped 10 percent in value on the Nasdaq after U.S. regulators FDA said the company’s experimental hepatitis C drug cures more patients than current therapies.

26 Apr 2011

New angle in cause of tuberculosis discovered - scientists hopeful for new therapy

In a new study published Monday, researchers from the US have isolated the enzyme that allows tuberculosis to destroy lung tissue. This discovery could speed the search for treatments.

26 Apr 2011

Most Americans unaware of recommended alcohol limits and risks of sea salt

Most Americans believe drinking wine is good for your heart but are unaware of recommended alcohol limits, and most mistakenly believe sea salt is a low-sodium alternative to regular table salt, according to a new survey about these common products.

26 Apr 2011

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Flu. The diagnostic test, which runs on Cepheid's GeneXpert® System, simultaneously detects and differentiates Influenza A, Influenza B, and the 2009 H1N1 influenza virus in about one hour.

26 Apr 2011

Accuray announces expiration of HSR waiting period for TomoTherapy acquisition

Accuray Incorporated, a global leader in the field of radiosurgery, today announced the expiration of the mandatory, pre-merger waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, in connection with the previously announced acquisition of TomoTherapy Incorporated.

26 Apr 2011

First Edition: April 26, 2011

Today's headlines include reports about the political ads and positions being inspired by the Ryan budget plan.

26 Apr 2011

Ohio State Roundtable to discuss about cancer drug development

The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Friends of Cancer Research are convening a high-level group of stakeholders to discuss current obstacles halting co-development of two or more experimental drugs for the treatment of cancer.

26 Apr 2011

Pharmacyclics receives Servier's $7 million milestone payment for HDAC inhibitor

Pharmacyclics, Inc. announced today that it has received a $7 million milestone payment for its histone deacetylase inhibitor, PCI-24781 / S 78454 from Les Laboratoires Servier based on an ex-US collaboration agreement signed in April of 2009.

26 Apr 2011

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

Caliber opens world's largest plant-made pharmaceutical facility in Bryan

Caliber Biotherapeutics, a fully-integrated biopharmaceutical company, announced the opening of the world's largest plant-made pharmaceutical manufacturing facility in Bryan, Texas, with the capability of producing 10-100 million doses of infectious vaccines per month, and hundreds of thousands of doses of protein biotherapeutics such as monoclonal antibodies.

26 Apr 2011

Multipolar electrocoagulation is a safe, effective therapy for Barrett's esophagus

A new study reports that multipolar electrocoagulation in combination with acid suppression is a safe and effective method to ablate nondysplastic Barrett's esophagus over the long term.

26 Apr 2011

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

26 Apr 2011

Researchers discover molecular mechanisms behind autoimmunity

Researchers from Boston University School of Medicine have discovered that human proteins with an affinity for Dermatan Sulfate have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

26 Apr 2011

African-American couples with HIV can benefit from health promotion interventions

Interventions to promote healthy behaviors, including eating more fruits and vegetables, increasing physical activity, and participating in cancer screenings, as well as prevention of HIV/sexually transmitted diseases, appear beneficial for African-American couples who are at high risk for chronic diseases, especially if one of the individuals is living with HIV.

26 Apr 2011

Men with high DHA levels may face risk of developing aggressive prostate cancer

The largest study ever to examine the association of dietary fats and prostate cancer risk has found what's good for the heart may not be good for the prostate.

26 Apr 2011

Alkem, Karo Bio partner to license eprotirome

Karo Bio has entered into a collaboration and license agreement with the Indian pharmaceutical company Alkem Laboratories Ltd.

26 Apr 2011

Dactinomycin more effective for low-risk gestational tumor treatment

A clinical trial has sifted out the most effective single-drug chemotherapy regimen for quick-growing but highly curable cancers that arise from the placentas of pregnant women.

26 Apr 2011

CSI's cancer cytogenetic testing receives COG approval

CSI Laboratories, a private national cancer diagnostics laboratory, has received approval from the Children's Oncology Group to begin analyzing pediatric cytogenetic cases. The Children's Oncology Group is the world's largest children's cancer research organization and includes more than 210 member hospitals with over 6,500 medical professionals.

26 Apr 2011

HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

26 Apr 2011